Shenyang Xingqi Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenyang Xingqi Ophthalmology Co., Ltd. is located in Qipanshan, Shenyang City, covering an area of approximately 76000 square meters. It is a national high-tech enterprise specializing in the research and development, production, and sales of ophthalmic drugs. On December 8, 2016, the company was listed on the Shenzhen Stock Exchange Growth Enterprise Board, with the securities abbreviation of Xingqi Eye Medicine and the securities code of 300573. The company adheres to the mission of "managing health and creating brightness"; Our vision is to become a globally competitive ophthalmic drug research and manufacturing enterprise; Practice the values of "responsibility, precision, persistence, innovation, and dedication" and actively invest in the human eye health industry. At present, the company's products include ophthalmic anti infective drugs, ophthalmic anti-inflammatory/anti infective drugs, artificial tears and eye lubricants, dry eye treatment drugs, nutrition and corneal repair drugs, mydriatic and ciliary muscle paralysis drugs, non steroidal anti-inflammatory drugs for ophthalmic use, pupil shrinking and anti glaucoma drugs, surgical eye irritants, etc., covering more than ten sub categories of ophthalmic drugs, providing high-quality products for the field of ophthalmic disease treatment. Innovation is the driving force for enterprise development. The company has Liaoning Provincial Enterprise Technology Center, Liaoning Provincial Professional Technology Innovation Center for Ophthalmic Drugs, and Liaoning Provincial Research Center for Myopia Prevention and Control for Children and Adolescents. In the field of ophthalmic drug research and development, it has built research platforms for conventional ophthalmic preparations, ready to use gel, sustained-release preparations, ophthalmic GLP laboratories, drug packaging materials, and other research platforms, with comprehensive ophthalmic drug research and innovation capabilities. In October 2020, the company's quality testing center was recognized by the China National Accreditation Service for Conformity Assessment (CNAS), indicating that the center has the ability to conduct experimental testing in accordance with the accreditation criteria. Quality comes from design, and high-quality products come from a constant pursuit of details. In 2014, the company's Qipanshan factory was fully put into use. The factory is designed according to the US FDAcGMP and EU GMP standards, and is jointly constructed by an international first-class design team, equipment suppliers, and engineering companies. It has extraction production line, single dose eye drops production line, multi dose eye drops production line, eye gel production line, eye solution production line, eye inner packaging material production line and other production lines that meet domestic GMP standards. The company is based on the research and production of ophthalmic drugs, market-oriented, and closely cooperates with domestic and foreign research institutes, medical institutions, and ophthalmic experts to promote the transformation of scientific research achievements; Promote and lead market sales through professional chemical techniques. Through a comprehensive marketing system and establishing cooperative relationships with distributors at all levels, the product sales network covers medical institutions at the provincial, municipal, and county-level levels nationwide. The rapidly changing Xingqi Eye Medicine strives to create long-term value for customers, employees, shareholders, partners, and society. On the basis of continuously improving itself, it shoulders the responsibility of promoting ethnic medicine in the era. Xingqiren, persistently striving to become a globally competitive ophthalmic drug research and manufacturing enterprise!. |
| Headquarter | Shenyang |
| Establish Date | 3/24/1977 |
| Listed Code | 300573.SZ |
| Listed Date | 12/8/2016 |
| Chairman | Liu Jidong. |
| CEO | Gao'e. |
| Website | www.sinqi.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
